Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical products company Taro Pharmaceutical Industries (TARO) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Taro and see what CAPS investors are saying about the stock right now.
Taro facts
Headquarters (founded) |
Haifa Bay, Israel (1959) |
Market Cap |
$2.4 billion |
Industry |
Pharmaceuticals |
Trailing-12-Month Revenue |
$688.4 million |
Management |
Interim CEO James Kedrowski |
Trailing-12-Month Operating Margin |
53.8% |
Cash/Debt |
$479.1 million / $28.3 million |
Competitors |
Perrigo |
On CAPS, 92% of the 50 members who have rated Taro believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star DrGoldin, succinctly summed up the Taro bull case for our community: "What's not to like? Margins and returns at the high end of the industry, with nothing but consistent growth for the future. All this at a modest p/e (however you wish to calculate it). And clean sheets!"
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.